The primary objective of this trial was to evaluate the efficacy and safety of two maintenance doses of immunologically enhanced , standardised quality ( SQ + ) grass subcutaneous immunotherapy ( SCIT ) [ 4,000 SQ + and 15,000 SQ + ; AVANZ ( ) Phleum pratense ( ALK ) ] compared with placebo .